A combo of two antibodies made from Eli Lilly hit all of its main and secondary goals in a recent study.
The trial, which included over 1,000 participants, showed that bamlanivimab and etesevimab reduced the risk of hospitalizations and death by 70 percent. The company also reported that the 10 patients who died during the study were taking a placebo — not the drug combo.
Lilly’s bamlanivimab has already won FDA approval and the combo is now currently under review. But the trial is ongoing with the goal of including 3,300 patients.
Read the Reuters report.
